A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

Roy M. Fleischmann; Nemanja S. Damjanov; Nils Kinnman

doi:10.1002/art.38949

doi.org/10.1002/art.38949

Clinical trial paper

A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

Roy M. Fleischmann,Nemanja S. Damjanov,Nils Kinnman

Arthritis & Rheumatology10.90

Volume: 67, Issue: 2, Pages: 334 - 343

Published: Nov 10, 2014

Paper Details

Title

A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

DOI

doi.org/10.1002/art.38949

Published Date

Nov 10, 2014

Journal

Arthritis & Rheumatology

Volume

67

Issue

2

Pages

334 - 343

Notes

History